(Q38112531)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23743084%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

meta-analysis

0 references

title

MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23743084%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

0 references

0 references

magnetic resonance imaging

0 references

author

Maria Pia Sormani

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23743084%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Paolo Bruzzi

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23743084%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

2

Paolo Bruzzi

1 reference

29 August 2017

Maria Pia Sormani

1

1 reference

29 August 2017

3 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23743084%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23743084%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23743084%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23743084%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

669-676

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23743084%20AND%20SRC:MED&resulttype=core&format=json

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

The validation of surrogate endpoints in meta-analyses of randomized experiments.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Time to first relapse as an endpoint in multiple sclerosis clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Oral fingolimod (FTY720) for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

A controlled trial of natalizumab for relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Placebo-controlled trial of oral laquinimod for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Surrogate endpoints in clinical trials: definition and operational criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Bayesian adaptive trial design for a newly validated surrogate endpoint

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Network meta-analysis models to account for variability in treatment definitions: application to dose effects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970103-0

7 January 2021

10.1016/S1474-4422(13)70103-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23743084%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference